Millions of people with Medicare and Medicaid could benefit from expanded coverage of GLP-1s for obesity Overall, CMSs efforts to expand Medicare and Medicaid coverage of GLP-1s for people with Medicare and Medicaid could greatly expand access to these drugs, albeit on a temporary basis, depending on the level of participation by drug manufacturers, state Medicaid agencies and Part D plans
"With orforglipron, we're working to transform obesity care by introducing a potential once-daily oral therapy that could support early intervention and long-term disease management, while offering a convenient alternative to injectable treatments," Kenneth Custer, an executive vice president and president of Lilly Cardiometabolic Health, said in a statement
[12] [21] Insulin remains the gold standard for diabetes management when oral agents are insufficient
Their global presence and clinical trial initiatives contribute to pipeline expansion
Want to take your transformation even further
Blueberries, strawberries, apples, pears, kiwi, etc., are incredible options
-1775582746855.png&w=384&q=75)
